Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $15

Author: Benzinga Newsdesk | November 03, 2023 07:22am
Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and lowers the price target from $22 to $15.

Posted In: VIR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist